Arcturus Therapeutics Announces Participation in 5th Annual mRNA-Based Therapeutics Summit Europe
Abogen
Nucleic Acid Drug Developer
AstraZeneca
Biopharmaceutical Manufacturer
BioNTech
Developer of Novel Biologics
Dr. Ying Bo, Founder, Chairman and CEO of Abogen, was invited to attend the event held in Berlin, Germany from January 28 to 29.5th Annual mRNA-Based Therapeutics Summit Europe。
The theme of the conference is“Boosting mRNA Potential for Therapeutics, Gene-Editing & Vaccine Applications With Scalable Design, Guided Delivery & Validated Clinical Safety”, Aiming to Advance mRNA Technology & Innovation Across Therapeutic Applications for Regulatory Approval.
This conference brings together many global leading pharmaceutical enterprises and biotechnology institutions, including AstraZeneca, BioNTech, Ethris, Fraunhofer Institute, and the European Union's Joint Research Centre (JRC). Over a hundred senior executives and scientific research experts will jointly lead the 2026 mRNA technology innovation wave through thematic discussions, in-depth exchanges, and strategic cooperation.
At the conference, Dr. Yingbo will be a featured expert, exchanging cutting-edge insights on next-generation RNA therapies with scientists and industry leaders from around the world. He will focus on how to overcome the barriers of long-term expression and dosage through self-replicating RNA and circular RNA technologies, while showcasing feasible pathways for their translation into applications for cancer and rare diseases.
Abogen Sharing Session
Keynote Speech
Keynote Speech
Subject:Unlocking the Therapeutic Power of Self-Amplifying & Circular RNA for Longer Expression and Lower Dosing
Time:January 29, 2026 9:30 a.m.
Summary:
① Exploring How Self-Amplifying RNA (saRNA) and Circular RNA (circRNA) Redefine the Potential of RNA Technology with Longer-Lasting Expression, Lower Doses, and Broader Applications；
② Understand the scientific and clinical significance behind specific modality challenges, covering key issues from immunogenicity to delivery complexity.
③Drawing on cutting-edge case research, learn how to translate next-generation RNA formats into viable therapies for cancer, rare diseases, and other fields.
This conference, as a top platform integrating cutting-edge breakthroughs, strategic cooperation, and industry insights, will systematically review the entire industrial chain development pathway of mRNA technology—from drug design and delivery innovation to clinical translation and commercialization—focusing on advanced fields such as personalized cancer vaccines and rare disease treatments. Abogen's deep involvement and sharing of frontier technologies not only highlight its leading position in the global RNA innovation field but also reflect the significant influence of Chinese mRNA companies on the international stage.
For more information, please visit the official website:
https://mrnabased-therapeutics-europe.com/
Related Reading
About Us
Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary mRNA and nanodelivery technology platforms and is one of the few mRNA drug R&D enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including cancer immunotherapy, autoimmune diseases, and infectious disease prevention and treatment.
